UCB’s Rozanolixizumab and Zilucoplan Phase 3 Generalized Myasthenia Gravis studies published in The Lancet Neurology Journal
MycarinG study publication reports the clinically meaningful and statistically significant effects of rozanolixizumab across key endpoints in adult patients with acetylcholine receptor autoantibody positive (AChR-Ab+) or muscle-specific tyrosine kinase (MuSK-Ab+) autoantibody positive gMG, in the largest study in patients with gMG to date. RAISE publication describes clinically meaningful and s